The in vitro effect of clindamycin on the inhibitory and bactericidal activity of amikacin (BB-K8) and gentamicin against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa was examined by the checkerboard technique in microtiter plates. Clindamycin (15 ,ug/ml) produced statistically significant increases in the minimal bactericidal concentrations of amikacin and gentamicin against E. coli and Klebsiellae at 2 and 4 h of incubation. The minimal bactericidal concentration against P. aeruginosa was not affected. Higher concentrations of clindamycin (20 to 25 ug/ml) reduced the minimal inhibitory and bactericidal concentrations of amikacin and gentamicin for E. coli at 18 h of incubation. The synergistic bactericidal activity of amikacin and carbenicillin against E. coli, but not P. aeruginosa, was also inhibited slightly by clindamycin (15 ,g/ml). The clinical implications of this inhibition of the early bactericidal in vitro activity of aminoglycosides by clindamycin remain to be determined. Although these in vitro results have not been studied in clinical infections, it is conceivable that slight interference in early bacterial killing could alter the outcome of infection in the immunosuppressed patient.
The increasing use of multiple antibiotics in hospitalized patients with serious sepsis has prompted consideration of possible synergy or antagonism of the antimicrobial activity of specific antibiotics. In many hospitals, clindamycin is added frequently to regimens of an aminoglycoside and a penicillin or cephalosporin in patients with suspected sepsis. This study examines the effect of clindamycin on the in vitro activity of two aminoglycoside antibiotics, gentamicin and amikacin (BB-K8), alone or in combination with carbenicillin, against strains ofEscherichia coli, Klebsiella, and Pseudomonas isolated from hospitalized patients.
(This paper was presented in part at the 14th Interscience Conference on Antimicrobial Agents and Chemotherapy, 12 September 1974, San Francisco, Calif.) MATERLALS AND METHODS Minimal inhibitory concentrations (MIC) and minimal bactericidal concentrations (MBC) at 2, 4, and 18 h of incubation were determined for amikacin (generously supplied by Karl Agre, Bristol Laboratories, Syracuse, N.Y.) and gentamicin in the presence of increasing concentrations of clindamycin (1 to 25 ,Ag/ml) (generously supplied by William Gouse, Upjohn Co., Kalamazoo, Mich.). Twenty strains of E. coli, 38 strains of K. pneumoniae, and 20 strains of P. aeruginosa isolated from patient specimens were studied. In a second set of experiments, the effect of 15 ,ug of clindamycin per ml on amikacin and carbenicillin in combination was examined at 2, 4, and 18 h of incubation with 9 strains of E. coli, 19 strains of K. pneumoniae, and 18 strains of P. aeruginosa. All strains were resistant to clindamycin.
For this study, a modification of the checkerboard technique in microtiter plates was used (4). Organisms previously stored on corked agar slants were grown overnight in Mueller-Hinton broth and then were diluted 1:100 for use in the microtiter wells. The final concentration of antibiotics also was diluted in Mueller-Hinton broth. The final volume in the microtiter wells was 200 IlI, consisting of25 ,ul of the appropriate dilutions of each antibiotic, 125 Al of diluent broth, and 25 ,ul of the bacterial suspension. When three antibiotics were studied in combination, the checkerboard technique was used for the aminoglycoside and carbenicillin concentrations. Clindamycin, to provide a concentration of 15 ,g/ml, was then added to each well. To keep all final volumes identical when an antibiotic was studied alone, an additional 25 Al ofdiluent broth was added to these wells. A sterile, 4-mm magnetic stirring rod was placed in each well prior to the addition of the appropriate dilutions. Placement of the microtiter plate on a magnetic stirrer results in rapid and simultaneous spinning ofthe rods and vigorous mixing of the well contents.
The microtiter plate with antibiotic-bacterial mixtures was incubated at 37 C and was withdrawn for sampling at 2, 4, and 18 h. The wells were mixed and sampled in duplicate with a replicator-type in-ANTIMICROB. AGENTS CHEMOTHZER.
oculator, specially constructed to fit the microtiter wells. At each sampling time, duplicate, antibioticfree Trypticase soy agar plates were inoculated with approximately 2 ,ul from each well. These agar plates were subsequently incubated at 37 C for 18 h ( Fig. 1) to determine the MBC. (A 99.9% killing was represented by two or fewer colonies at the inoculation site, based on the calculated number of organisms inoculated in each well.) Direct inspection of the microtiter wells for turbidity after 18 h of incubation was used to determine the MIC.
The reproducibility of this microtiter method was studied as follows. The MIC (after 18 h of incubation) and MBC (at 4 and 18 h of incubation) were determined for the same antibiotic-bacterial combination in 10 replicate samples. The synergistic combination (amikacin and carbenicillin), as well as the antagonistic combination (amikacin and clindamycin), was studied in this fashion. The MIC, 4-h MBC, and 18-h MBC determinations agreed within one dilution for each of the 10 replications. The reproducibility of this method compares favorably with the tube dilution-pour plate technique. The definitions of synergy and antagonism for the purpose of this paper are those of Sabath (4) .
The rate of the antibiotic killing by amikacin alone and in the presence of clindamycin (15 gg/mi) was determined with a spot plate method, which compares favorably with the standard pour plate technique and allows multiple organism-antibiotic combinations to be studied simultaneously. In brief, quantitative samples (5 id) of the antibiotic-bacterial mixture are removed from the incubator at timed intervals and spot plated on an antibiotic-free agar plate. To prevent spreading of the colonies, an additional drop of agar is placed over the spot inoculum. This plate is incubated for-4 h and the microcolonies are counted with the aid of a microfiche viewer. The number of organisms present in the mixture is determined by multiplication by the dilution factor. Analysis ofvariance for this method and the standard pour plate method for bacterial killing curves showed that the two methods are equally variable (Zinner et al., Proc. 9th Int. Congr. Chemother., London, England, in press).
RESULTS
The 18-h inhibitory and the early and late bactericidal activities of increasing concentrations of amikacin and of clindamycin are plotted as isobolograms in E. coli and 38 strains of K. pneumoniae were studied. Each point plotted represents the geometric mean concentration of each antibiotic in the combination required to produce a given biological effect (i.e., inhibition or killing after 4 or 18 h). The isobol representing bactericidal activity at 4 h of incubation demonstrates the antagonistic effect of clindamycin on the activity of the aminoglycoside against E. coli and Klebsiellae, respectively. Although the strains tested were extremely sensitive to amikacin, the inhibitory effect is seen at concentrations of clindamycin equal to or greater than 5 ug/ml. This effect is most pronounced at higher concentrations. However, after 18 h of incubation, no in vitro antagonism is seen and, in fact, very high concentrations of clindamycin (20 to 25 ,g/ml) decrease both the MIC and MBC for these organisms. Similar results were obtained with clindamycin and gentamicin for E. coli but not for Klebsiellae. Clindamycin had no inhibiting effect on the killing of 20 strains ofP. aeruginosa by either amikacin or gentamicin.
The synergistic bactericidal effect of amikacin and carbenicillin against 9 strains ofE. coli at 4 h was significantly inhibited by clindamycin at 15 ,g/ml (Fig. 3) . This inhibition was not seen at 18 h of incubation (not shown). The synergistic bactericidal and inhibitory activity of amikacin and carbenicillin for P. aeruginosa was not affected by this concentration of clindamycin at any incubation time.
As presented in Fig. 4 , clindamycin (15 ,g/ ml) significantly slowed the early killing of 10 strains each ofE. coli and Klebsiellae. No effect was found on the rate of killing of 10 strains of Pseudomonas (not shown). A slight increase in viable count at 0.5 h was seen in the E. coli treated with amikacin alone but not with amikacin plus clindamycin.
DISCUSSION
These data suggest that clindamycin over a wide range of clinically achievable concentrations may interfere with the early in vitro killing ofE. coli and Klebsiellae by the aminoglycoside antibiotics amikacin and gentamicin. Clindamycin may reach 15 to 20 ,ug/ml in the serum of patients treated with intravenous clindamycin phosphate (5) . At concentrations of 20 to 25 ,ug/ml, however, clindamycin has a slight enhancing effect on the activity of these agents at later periods of incubation. Clindamycin did not interfere with the activity of either aminoglycoside against Pseudomonas at any phase of the incubation period. Clindamycin at 15 jig/ml slowed slightly the rate of bacterial killing by amikacin against strains ofE. Sabath and Toftegaard (6) 
